A
SMMT icon

AlphaQuest’s Summit Therapeutics SMMT Stock Holding History

AlphaQuest’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,188
Closed -$108K – 1773
2025
Q4 		$108K Sell
6,188
-13,108
-68% -$247K 0.01% 1715
2025
Q3 		$399K Buy
19,296
+13,405
+228% +$325K 0.03% 958
2025
Q2 		$125K Buy
5,891
+3,349
+132% +$76.4K 0.01% 1352
2025
Q1 		$49K Buy
+2,542
New +$51K 0.01% 1537

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

AlphaQuest's SMMT Position: Q1 2026 in Review

AlphaQuest sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 6,188 shares — an estimated $108K sold.

AlphaQuest first reported a position in SMMT in Q1 2025 and held it in 4 quarters. The position peaked at $399K in Q3 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • AlphaQuest reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 6,188 Summit Therapeutics shares in Q1 2026, an estimated $108K.
  • AlphaQuest first reported a position in Summit Therapeutics in Q1 2025 and held it in 4 quarters.
  • AlphaQuest's Summit Therapeutics position peaked at $399K in Q3 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.